证券代码：600803 证券简称：新奥股份 公告编号：临 2025-054 本次交易的股票交易自查期间为上市公司本次重组停牌前 6 个月至重组报告书披 露之前一日止，即自 2024 年 9 月 19 日至 2025 年 4 月 25 日。 二、本次交易的内幕信息知情人核查范围 新奥天然气股份有限公司 关于本次交易相关内幕信息知情人买卖股票情况的 自查报告的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 新奥天然气股份有限公司（以下简称"公司" "上市公司"或"新奥股份"）拟通过 全资子公司私有化新奥能源控股有限公司（股票代码：02688.HK，以下简称"标的公 司"），并以介绍上市方式在香港联合交易所有限公司主板上市（以下简称"本次交易" "本次重组"）。 根据《上市公司重大资产重组管理办法》《公开发行证券的公司信息披露内容与格 式准则第 26 号——上市公司重大资产重组》及《监管规则适用指引——上市类第 1 号》 等文件的规定，公司对本次交易涉及的相关内幕信息知情人买卖公司股票进行核查，现 就查询情况公告如下： 一、本 ...

每经评论员 杜宇 笔者认为，ST联合应详细披露重组计划的具体细节，包括资金来源、整合方案、业绩承诺与补偿机 制、提供详细的决策流程和人员信息，以便公众和监管机构能够清楚地了解到决策的全过程，澄清市场 疑虑。此外，公司还需向投资者充分说明此次重组对改善公司业绩、提升市场竞争力的具体作用，避免 投资者因信息不对称而产生不必要的恐慌或盲目跟风。 5月14日晚间，ST联合（SH600358，前收盘价4.73元，市值：23.88亿元）发布公告称，公司筹划以发行 股份及支付现金的方式购买江西润田实业股份有限公司（以下简称润田实业）部分或全部股权并募集配 套资金，预计构成重大资产重组和关联交易。然而，就在公告发布的当天，ST联合股价提前涨停，这 一异常表现引发了市场对内幕交易的强烈质疑。 根据相关规定，上市公司在发布重要公告之前，应当严格保密，避免信息泄露。然而，ST联合在5月14 日收盘时股价涨幅达5.11%，而公司是晚间才发公告宣布谋划重大资产重组，某些人的先知先觉，引发 了市场对内幕交易的质疑。 值得注意的是，ST联合近年来的业绩表现不佳，2023年至2025年第一季度归母净利润持续亏损，分别 为-1696.05万元 ...

Group 1 - The core viewpoint emphasizes the importance of protecting the legal rights of small and medium investors as a foundation for the sustainable and healthy development of the capital market [1] - The current legal framework for protecting small and medium investors is expected to become more robust and effective [1] Group 2 - Small and medium investors are at a disadvantage in terms of investment experience, information access, and analytical skills, making them vulnerable to violations such as false statements, insider trading, and market manipulation [2] - From March 2021 to March 2025, the Beijing Financial Court accepted 9,101 cases of securities fraud liability disputes, with 9,077 cases (99.7%) related to securities false statement liability [2] Group 3 - The legal system for false statement civil lawsuits is more developed, leading to a higher number of lawsuits related to false statements compared to other violations [3] - Investors can also seek compensation for losses caused by insider trading and market manipulation under the Securities Law [3] Group 4 - The Supreme People's Court's new regulations have removed the pre-litigation procedures for false statement civil lawsuits, allowing investors to file lawsuits without waiting for administrative or criminal penalties [4] - The main challenge in these cases lies in the burden of proof, particularly in establishing causation and loss [4] Group 5 - The introduction of the new regulations is expected to ease the burden of proof for investors, but it will take time for the system to fully implement these changes [5] - Future improvements in the litigation process and better communication between lawyers, courts, and regulatory bodies are anticipated [5] Group 6 - The new Securities Law has established mechanisms for representative lawsuits and special representative lawsuits to address collective disputes among investors [6] - The Beijing Financial Court is exploring an innovative "dual-track dual-platform" mechanism for resolving collective disputes, combining representative lawsuits with demonstration judgment mechanisms [6] Group 7 - Both representative lawsuits and demonstration judgments can enhance trial efficiency and reduce the cost of rights protection for investors [7] - The Supreme Court and the Securities Regulatory Commission have established a diversified dispute resolution mechanism to provide alternatives to litigation for investors [7] Group 8 - In false statement liability disputes, accurately identifying the responsible parties is crucial for protecting investors' rights and increasing the cost of violations [8] - The determination of civil liability among various defendants, including issuers and intermediaries, is a key focus in these cases [8] Group 9 - Recent judicial practices have introduced proportional joint liability to determine the responsibility of intermediary institutions in false statement cases [9] - This approach considers the subjective fault of the intermediary and the causal relationship between their negligence and the resulting damages [9] Group 10 - There is often a discrepancy between the amount compensated and the actual losses incurred by investors, which can be confusing [10] - The court determines compensation based on the actual losses incurred due to false statements, which may not cover all losses experienced by the investor [10] Group 11 - The legal basis for claims related to securities false statements is tort liability, which requires precise determination of damages and causation [11] Group 12 - The increase in civil compensation cases related to market manipulation and insider trading highlights the need for judicial interpretations in these areas [12] - The current Securities Law includes provisions for civil liability related to insider trading and market manipulation, but remains somewhat general [12] Group 13 - There is ongoing academic debate regarding the necessity of judicial interpretations for civil compensation related to insider trading and market manipulation [13] - Establishing a clear framework for civil liability in these cases is essential for ensuring investor compensation [13]

证券代码：000422 证券简称：湖北宜化 公告编号：2025-049 湖北宜化化工股份有限公司 关于本次重组相关主体买卖股票情况自查 报告的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、 完整，没有虚假记载、误导性陈述或重大遗漏。 特别提示： 根据中国证券登记结算有限责任公司深圳分公司出具的《信息披 露义务人持股及股份变更查询证明》《股东股份变更明细清单》、本 次交易相关内幕知情人等相关方出具的自查报告、存在买卖情形的相 关机构和人员出具的声明及承诺等文件，在上述内幕信息知情人等相 关方出具的自查报告及相关声明真实、准确、完整的前提下，上述相 关自然人和机构在自查期间买卖湖北宜化化工股份有限公司（以下简 称"上市公司"或"湖北宜化"）股票的行为不会对本次交易构成实 质性障碍；除上述情况外，纳入本次交易核查范围内的其他内幕知情 人在自查期间不存在于二级市场买卖湖北宜化股票的情况；本次重组 不存在因涉嫌内幕交易被中国证监会立案调查或者被司法机关立案 侦查的情形，符合《深圳证券交易所上市公司自律监管指引第 8 号— —重大资产重组（2025 年修订）》之相关规定。 湖北宜化拟支付现金购买控股股东湖北宜 ...

Group 1 - The core issue revolves around the investigation of the controlling shareholder, Jiang Wei, for insider trading, which has raised concerns about potential related party transactions and market trust in the company [1][2] - The company reported a significant decline in revenue growth, with a 1.64% increase projected for 2024, marking a four-year low, while traditional business segments are experiencing revenue declines [2][3] - The company's reliance on acquisitions for growth is being questioned, as the integration of acquired entities has shown mixed results, and R&D investment has decreased significantly [3][4] Group 2 - The company faces internal challenges, including governance issues and declining performance, while external pressures from industry competition and pricing strategies are intensifying [4] - The medical aesthetics sector is becoming increasingly competitive, with other players also facing challenges, indicating a potential end to the high-growth phase for hyaluronic acid products [3][4] - To regain market confidence, the company must address compliance, innovate in R&D, and diversify its business operations [4]

5月8日，身处控制权更迭中的康惠制药（603139.SH)在北京酒仙桥注册了新的子公司，业务聚焦科技人 工智能与中药毫无关联，名称中的"智创"字样则与收购方名称（悦和智创）一脉相承。 相关细节正折射一种可能：虽然转让控制权的交易仍在等待交易所的审查与确认，理论上尚存不确定 性，但公司已经按照易主成功完成来启动业务布局。 康惠制药这次易主事件，属于典型的"小公司，大戏码"。新崛起的"算力新贵"携真金白银完成了对传统 中药大佬的逆袭，而卡在财报季最后，康惠制药拿出一份行业垫底、经营崩塌之惨烈超预期的成绩单， 则让交易各方真实目的越来越难以遮掩：套现方急于速战速决，接盘方图的就是个"壳"。 前文《康惠制药：迷途中易主，"遗老"与"新贵"的资本联姻术》，梳理了一个靠保健品生意起家的传 统"药人"，如何在运营上市企业过程中陷入并购迷途，最终只能靠卖掉企业套现来完成最后一搏； 也对这场资本联姻的逻辑进行剖析：一对算力公司实控人夫妇，通过一个当天成立的合伙企业，以外界 眼中非理性高价（24.70元/股）豪掷5.43亿，来收购一家财务恶化的中药上市公司——同时不管你信不 信，坚称其目的不是借壳。 本文则聚焦这场控制权变更"速 ...

资料来源：赣锋锂业 2024年度可持续发展报告 编者按：ESG年报解读为搜狐财经及价值公司100联合发起的针对各公司ESG报告披露情况的解读专 栏。 参考上交所《上市公司治理准则》、港交所《环境、社会及管治守则》等文件，搜狐财经迭代完善各行 业ESG测评体系标准，并以最新标准为依托，以2024年公司ESG报告为主要数据来源，对公司环境资 源、社会责任及公司管治进行了评价。 本文为"赣锋锂业"篇。 出品 | 搜狐财经 研究员 | 张子豪 近期，"锂矿双雄"双双公布2025年一季报。赣锋锂业营收37.72亿元，同比下滑25.43%，亏损3.56亿元； 天齐锂业营收25.84亿元，与上年同期持平，净利润1.04亿元，已实现扭亏为盈。 2024年，赣锋锂业面临全球锂行业的深度调整，也迎来了上市15年来首次年度亏损。全年营收189亿 元，同比下滑42.66%，归母净亏损20.74亿元，资产负债率攀升至52.8%的历史高位。 2024年至今，赣锋锂业面临内幕交易行为的行政处罚，以及金融衍生品操作的损失等挑战。本文结合赣 锋锂业2024年度可持续发展报告，从ESG视角分析赣锋锂业的相关情况。 赣锋锂业涉内幕交易被罚，高管合 ...

昊海生科展馆视觉中国供图 羊城晚报记者 汪海晏 近日，上海昊海生物科技股份有限公司（以下简称"昊海生科"）发布公告称，公司控股股东、实际控制 人之一蒋伟因涉嫌内幕交易，被中国证监会立案调查，但此事与公司股票无关。 不过，尽管蒋伟本人并不在上市公司担任具体职务，也不参与公司日常经营管理，公司日常运作由以侯 永泰、吴剑英为核心的专业管理团队负责。但作为创始人与实控人，蒋伟对公司发展方向有着深远影 响。 早期，昊海有限公司通过引入上海华源生命科学研究开发有限公司完成首次增资，切入医用透明质酸钠 （即玻尿酸）领域。此后，昊海生科开启频繁的并购扩张之路，在眼科领域，2015-2021年间接连收购 昊海生科在公告中特别强调："本次事项系对蒋伟先生个人的调查，其不参与公司日常经营管理，该事 项不会对公司日常经营活动产生重大影响。"尽管公司极力撇清与该事件的关系，但资本市场迅速作出 反应。截至5月9日收盘，A股昊海生科股价收报52元，下跌0.5%，总市值121亿元；港股股价则下跌 1.69%。 5月11日，羊城晚报记者就该事件对公司带来的影响、公司目前的应对措施、未来战略规划等相关问题 采访昊海生科，截至发稿未收到回复。 实 ...

证券代码：300121 证券简称：阳谷华泰 公告编号：2025-071 债券代码：123211 债券代码：阳谷转债 山东阳谷华泰化工股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 山东阳谷华泰化工股份有限公司（以下简称 "公司"、"上市公司"或"阳 谷华泰"）拟通过发行股份及支付现金方式购买波米科技有限公司（以下简称"波 米科技"或"标的公司"）100%股权并募集配套资金（以下简称"本次交易"或 "本次重组"）。 根据《上市公司重大资产重组管理办法》《上市公司监管指引第 7 号——上 市公司重大资产重组相关股票异常交易监管》《公开发行证券的公司信息披露内 容与格式准则第 26 号——上市公司重大资产重组》 《监管规则适用指引——上市 类第 1 号》等法律、法规的要求，上市公司对本次交易相关内幕信息知情人买卖 上市公司股票的自查报告进行了核查，具体如下： 一、本次交易的内幕信息知情人买卖股票情况的自查期间 本次交易自查期间为自上市公司首次披露本次重组事项或就本次重组申请 股票停牌（孰早）前六个月至《山东阳谷华泰化工股份有限公司发行股份及支付 现金购 ...

Core Viewpoint - The company is facing significant challenges due to the investigation of its controlling shareholder for insider trading, alongside declining performance in key business segments and increasing competition in the industry [1][5][6]. Financial Performance - The company's overall revenue growth has slowed, with 2024 revenue at 2.698 billion (up 1.64% year-on-year) and net profit at 420 million (up 1.04% year-on-year) [2]. - In Q1 2025, revenue dropped to 619 million (down 4.25% year-on-year) and net profit to 90 million (down 7.41% year-on-year) [2]. - R&D expenses decreased significantly by 25.4%, while sales and management expense ratios increased by 0.54 and 1.52 percentage points, respectively [2]. Business Segmentation - The medical aesthetics segment showed weak growth, with 2024 revenue at 1.2 billion (44.38% of total), and hyaluronic acid product revenue at 742 million (up 23.23% year-on-year), but a sharp decline from 95.45% growth in 2023 [3]. - The ophthalmology segment reported revenue of 858 million (down 7.60% year-on-year), with intraocular lens revenue at 328 million (down 14.06% year-on-year), primarily impacted by a 60% price drop from the fourth national procurement [3]. - The orthopedics segment generated revenue of 457 million (down 4.11% year-on-year), with profits affected by price declines from provincial procurement for sodium hyaluronate injections [4]. Dividend and Market Concerns - The company's high dividend payouts have raised market concerns, with the controlling shareholder couple receiving approximately 344 million in cash dividends from 2019 to 2024, and the 2024 dividend accounting for 54.92% of net profit [4]. Industry Risks - The investigation into the controlling shareholder poses risks, including potential stock freezes or selling restrictions, which could undermine market confidence and highlight governance issues due to concentrated ownership [5][6]. - The company faces intense competition in the medical aesthetics sector, with rivals like Huaxi Biological and Aimeike, and pressure from new technologies impacting traditional markets [6]. - The normalization of centralized procurement is leading to a downward price trend for ophthalmology and orthopedics products, necessitating faster innovation to maintain profit margins [7]. Cash Flow and Asset Quality - Concerns regarding cash flow and asset quality are evident, with accounts receivable at 316 million (75.18% of net profit) and a low inventory turnover rate of 0.39 times [8]. - In Q1 2025, operating cash flow was 86 million, while cash outflow from investment activities was 179 million [8].